NTRK Fusion mutation ( Brain cancer, thyroid cancer, lung cancer, hepatobiliary tumors, gastrointestinal cancer, colorectal cancer)
NTRK（NeuroTrophin Receptor Kinase） It is a neurotrophic factor receptor tyrosine kinase. The tropomyosin receptor kinase (TRK) family includesTRKA、TRKB AndTRKC Three types of proteins, each consisting ofNTRK1、NTRK2 AndNTRK3 Gene coding, these proteins typically appear in neural tissue. If the above genes undergo fusion mutations with other genes, it can lead to abnormal activity and drive the occurrence of tumors. NTRK Gene fusion can occur in any part of the body, including solid tumors in adults and children, such as brain tumors, thyroid cancer, lung cancer, liver and gallbladder tumors, gastrointestinal cancer, colorectal cancer, etc. It is estimated that there are0.2% of span class="s1"> NSCLC The patient existsNTRK Fusion, usually not with other oncogenic driver genes (such asEGFR、ALK OrROS1） Simultaneously existing.
Targeted therapeutic drugs：
Larotrectinib is the first productFDA Approved regardless of age and cancer type and targeted towardsNTRK Broad spectrum fusionTRK Inhibitors. 2019 Year'sNCCN Guidelines have been updated to include LalotinibNTRK The first-line treatment for fusion positive non-small cell lung cancer. Entretinib has been awarded in JapanFDA AndEMA Approval for treatmentNTRK Adult and pediatric patients with fusion positive, late stage recurrent solid tumors, andROS1 The treatment of positive metastatic non-small cell lung cancer (NSCLC) patients is the second global product to be launched and targeted after LarotrectinibNTRK A broad-spectrum anti-cancer drug that fuses mutated solid tumors. Compared to using Larotrectinib, Entretinib increases targetingROS1 Indications for non-small cell lung cancer with fusion mutations.